Factor ix complex - Biologic Drug Details

Summary for factor ix complex

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for factor ix complex Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for factor ix complex Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for factor ix complex Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Factor IX Complex

Last updated: February 20, 2026

What is Factor IX Complex?

Factor IX complex (also known as prothrombin complex concentrate, PCC) is a biologic used to reverse the effects of anticoagulants such as warfarin, treat certain bleeding disorders, and manage coagulation deficiencies. It comprises coagulation factors II, IX, and X, and sometimes factor VII.

Market Size and Growth Drivers

Global Market Valuation (2022)

Segment	Valuation (USD billions)	Notes
Total PCC market	1.2	Includes all formulations
Post-surgical bleeding	0.5	Major application
Bleeding disorder treatments	0.4	Hemophilia B, other conditions

Compound Annual Growth Rate (CAGR)

• Estimated CAGR (2023–2030): 8.5% (Grand View Research)
• Market expansion driven by:
  • Increasing prevalence of anticoagulation therapy
  • Rising incidence of bleeding disorders
  • Development of next-generation PCC products

Regional Breakdown

Region	Market Share	Key Factors
North America	45%	High anticoagulant use, advanced healthcare infrastructure
Europe	35%	Aging population, regulatory approvals
Asia-Pacific	12%	Growing healthcare access, emerging markets
Rest of World	8%	Limited adoption, cost barriers

Key Market Trends and Influences

Increased Use in Anticoagulation Reversal

Warfarin and direct oral anticoagulants (DOACs) pose bleeding risks requiring rapid reversal agents. PCCs are preferred over plasma due to faster action and lower volume requirements.

Therapeutic Improvements

Manufacturers are developing safer, high-purity PCCs with reduced thrombotic risks, expanding their clinical applications.

Regulatory Environment

• US FDA approved several PCCs for warfarin reversal (e.g., Octaplex, Kcentra).
• European Medicines Agency (EMA) guidelines support PCC use for bleeding management.
• Ongoing trials for recombinant and plasma-derived PCCs.

Competitive Landscape

Company	Product Name	Market Share	Key Innovations
CSL Behring	Kcentra	Leading	Fast infusion times, recombinant options
Grifols	Octaplex	Significant	High-purity formulations, broad distribution channels
Pfizer (formerly)	Bebulin VH	Moderate	Extended shelf life, improved safety profile

Patent and Pricing Dynamics

• Patent expirations for some formulations (post-2025) risk generic entry.
• Price per dose ranges from $1,200 to $2,500 depending on formulation and region.
• Insurance coverage and hospital procurement strategies influence accessibility.

Financial Trajectory and Investment Outlook

Revenue Projections (2023–2030)

• Compound revenue expected to grow from approximately USD 1.2 billion to USD 2.5 billion.
• Major growth contributors:
  • Adoption of PCCs for DOAC reversal
  • Emergence of recombinant PCCs
  • Expansion into emerging markets

R&D Investment Patterns

• Companies investing 10-15% of revenue in R&D (e.g., CSL Behring, Grifols).
• Focus areas include:
  • Recombinant factor IX complexes
  • Improvements in safety and efficacy
  • Alternative delivery methods

Risks and Challenges

• Thrombotic complications associated with PCC use.
• Regulatory delays in approval cycles.
• Market entry barriers from entrenched competitors.
• Cost pressure due to patent expiries and generic competition.

Patent Landscape and Regulatory Considerations

Patent Expiry (Approximate)	Focus	Impact
2025–2028	Plasma-derived PCC formulations	Potential for generic biosimilar development
2023–2026	Recombinant PCC innovations	Encourages innovation, prolongs exclusivity

Regulatory agencies require rigorous safety data, especially concerning thrombosis risks, influencing product development timelines and costs.

Key Takeaways

• The Factor IX complex market is expanding at a double-digit CAGR, driven by anticoagulant reversal needs and bleeding disorder treatments.
• Innovation in recombinant formulations and safety improvements remains key to capturing market share.
• Pricing strategies and patent protections significantly impact revenue potential.
• Regulatory pathways influence timelines and investment risks.
• Geographic growth hinges on healthcare infrastructure, regulatory approvals, and cost policies.

FAQs

1. What are the main clinical uses of Factor IX complex?
   Used primarily for warfarin reversal, management of bleeding in hemophilia B, and certain surgical procedures requiring rapid coagulation control.

2. How does recombinant PCC differ from plasma-derived versions?
   Recombinant PCCs are produced in cell culture, eliminating plasma-associated risks and offering potentially higher purity and consistent activity.

3. What are the main safety concerns with PCCs?
   Thrombotic events are the primary risk, especially with high dosing or in susceptible patients.

4. Which regions are expected to see the fastest market growth?
   Asia-Pacific and Latin America due to expanding healthcare access and increasing anticoagulant use.

5. How might patent expirations affect the market?
   Generic biosimilars could reduce prices and margins, increasing competition but potentially decreasing revenue for incumbent companies.

---

References

1. Grand View Research. (2022). Prothrombin Complex Concentrate Market Size, Share & Trends Analysis Report.
2. U.S. Food and Drug Administration. (2022). Kcentra (Prothrombin Complex Concentrate), Prescribing Information.
3. European Medicines Agency. (2021). Guidelines on coagulation factor products.
4. Smith, J., & Lee, R. (2022). Market trends in coagulation factor therapies. Journal of Hematology, 10(2), 109–115.
5. PharmaFocus. (2023). Competitive landscape for PCCs: Innovation and regulation.